<DOC>
	<DOCNO>NCT00027963</DOCNO>
	<brief_summary>RATIONALE : Gabapentin may effective relieve pain symptom peripheral neuropathy . It yet know gabapentin effective treat peripheral neuropathy cancer patient undergo chemotherapy . PURPOSE : Randomized phase III trial determine effectiveness gabapentin treat pain symptom peripheral neuropathy cancer patient undergo chemotherapy .</brief_summary>
	<brief_title>Gabapentin Treating Peripheral Neuropathy Cancer Patients Undergoing Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether gabapentin improve pain symptom cancer patient chemotherapy-induced peripheral neuropathy . - Determine effect drug symptom distress , mood state , functional ability , overall quality life patient . - Determine toxic effect drug patient . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord neurotoxic chemotherapy ( active v nonactive discontinue vs complete ) neurotoxic chemotherapeutic agent ( vinca alkaloid vs taxanes v platinum-based compound vs combination two agent ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive titrate dos oral gabapentin twice daily three time daily 3 week . Patients receive fix dose oral gabapentin three time daily 3 week . Patients cross-over therapy arm II week 8 . - Arm II : Patients receive titrate dos oral placebo fix dose oral placebo arm I . Patients cross-over therapy arm I week 8 . Quality life assess baseline end week 6 , 8 , 14 . PROJECTED ACCRUAL : A total 100 patient ( 50 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Has receive currently receive neurotoxic chemotherapy , include taxanes ( e.g. , paclitaxel docetaxel ) , platinumbased compound ( e.g. , carboplatin , cisplatin , oxaliplatin ) , vinca alkaloid ( e.g. , vincristine vinblastine ) Pain symptoms peripheral neuropathy least 1 month duration attribute chemotherapyinduced peripheral neuropathy Average daily pain rating least 4 10 use pain numerical rating scale ( 0 pain 10 bad pain possible ) OR Evidence peripheral neuropathy least grade 1 3 ECOG Common Toxicity Criteria sensory neuropathy No identified cause painful paresthesia exist prior chemotherapy No radiotherapyinduced malignant plexopathy No lumbar cervical radiculopathy No preexist peripheral neuropathy another etiology , include : B12 deficiency AIDS Monoclonal gammopathy Diabetes Heavy metal poison Amyloidosis Syphilis Hyperthyroidism hypothyroidism Inherited neuropathy PATIENT CHARACTERISTICS : Age : 18 Life expectancy : At least 6 month Renal : Creatinine great 1.5 time upper limit normal Other : No prior allergic reaction intolerance gabapentin No significant psychiatric illness ( e.g. , mania , psychosis , schizophrenia ) would preclude study compliance No extreme difficulty swallow pill Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Other : More 30 day since prior investigational agent pain control Concurrent selective serotonin reuptake inhibitor allow Concurrent nonsteroidal antiinflammatory drug allow No concurrent tricyclic antidepressant ( e.g. , amitriptyline , nortriptyline , desipramine ) * No concurrent monoamine oxidase inhibitor* No concurrent opioid analgesic* No concurrent adjuvant analgesic ( e.g. , anticonvulsant , clonazepam , mexiletine ) * No concurrent topical analgesic ( e.g. , lidocaine gel lidocaine patch ) * No concurrent amifostine No concurrent investigational agent pain control NOTE : * For pain symptom due chemotherapyinduced peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>neurotoxicity</keyword>
	<keyword>pain</keyword>
</DOC>